Literature DB >> 2483686

Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased.

K S Tonkin1, G J Rustin, B Wignall, F Paradinas, M Bennett.   

Abstract

Enlargement of tumour masses with a fall or no change in tumour marker levels was noted in eight of 287 patients during chemotherapy for NSGCT at the Charing Cross and Mount Vernon Hospitals between 1977 and 1988. These eight patients had elements of differentiated teratoma in the primary specimen and in five the enlarging masses showed cystic change on CT scan. The increase in tumour mass occurred within 6 months of starting treatment. At surgery, four patients were found to have differentiated teratoma and have been followed for 15 months to 5 years without relapse. Two patients who also had some areas of embryonal carcinoma in the resected specimens had post-operative chemotherapy and are alive disease free at 8 and 24 months respectively. Two patients died: one post-operatively of uncontrolled haemorrhage secondary to aortic rupture and the second of acute myeloid leukaemia following 8 years of intermittent therapy for unresectable differentiated teratoma. The successful outcome in six of these eight patients suggests that enlarging teratomatous masses on chemotherapy can be managed by surgical resection and, when active tumour is present, by the use of post-operative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2483686     DOI: 10.1016/0277-5379(89)90343-x

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

1.  Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

Authors:  Stewart Goldman; Eric Bouffet; Paul G Fisher; Jeffrey C Allen; Patricia L Robertson; Paul J Chuba; Bernadine Donahue; Cynthia S Kretschmar; Tianni Zhou; Allen B Buxton; Ian F Pollack
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

2.  Recurrence of immature ovarian teratoma as malignant follicular carcinoma with liver and peritoneal metastasis 22 years after completion of initial treatment.

Authors:  Nicholas Brian Shannon; Norman Hok Ling Chan; Melissa Ching Ching Teo
Journal:  BMJ Case Rep       Date:  2017-10-24

Review 3.  Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis.

Authors:  J P Donohue; E P Fox; S D Williams; P J Loehrer; T M Ulbright; L H Einhorn; T D Weathers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

4.  The growing teratoma syndrome secondary to immature teratoma of the ovary.

Authors:  Tsutomu Inaoka; Koji Takahashi; Tomonori Yamada; Naoyuki Miyokawa; Yoshihiko Tokusashi; Makoto Yoshida; Masaya Sugimoto; Kazutoshi Miyamoto; Tamio Aburano
Journal:  Eur Radiol       Date:  2002-10-15       Impact factor: 5.315

5.  Ovarian germ cell tumors with rhabdomyosarcomatous components and later development of growing teratoma syndrome: a case report.

Authors:  Usama Al-Jumaily; Maysa Al-Hussaini; Fatenah Ajlouni; Abdulrahman Abulruz; Iyad Sultan
Journal:  J Med Case Rep       Date:  2012-01-16

6.  Growing teratoma syndrome: a rare case report and review of the literature.

Authors:  Nirmala Kampan; Trika Irianta; Arifuddin Djuana; Lim Pei Shan; Mohd Hashim Omar; Ahmad Zailani Hatta Mohd Dali
Journal:  Case Rep Obstet Gynecol       Date:  2012-05-08

7.  The growing teratoma syndrome: Current review of the literature.

Authors:  Vladislav Gorbatiy; Philippe E Spiess; Louis L Pisters
Journal:  Indian J Urol       Date:  2009-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.